DLA Piper partners advise Pfizer on $635m vaccines acquisition from Baxter
DLA Piper has advised Pfizer on the $635m (£405m) acquisition of commercial vaccines from Baxter. The deal included the meningitis prevention vaccine NeisVac-C and the well-known vaccine FSME-IMMUN/Ticovac. Furthermore, Pfizer acquired the production facility in Austria where the two vaccines are manufactured. The transaction was led by DLA Piper partners Christoph Mager and Elisabeth Stichmann, […]